Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism
R. Patel, L. Rodgers, C. A. Ford, L. Rushworth, J. Fleming, E. Mui, T. Zhang, D. G. Watson, G. MacKay, D. Sumpton, O. J. Sansom, H. Y. Leung
This study identifies cyclocreatine as a dual-action inhibitor of prostate cancer by blocking the phosphagen system and increasing S-adenosyl methionine levels.
bioRxiv · Feb 26, 2021 · PreprintCancer Biology